Global

Dermatology Experts

Andrew Mackie

Chief Business Officer
Healthcare
CLC Bio
Aruba

Biography

 Andrew Mackie joined Ergomed as Chief Business Officer in 2015 having worked with the company as a consultant since 2004. He has been instrumental in developing the co-development business and negotiating the partnerships signed to date. Andrew joins from the Business Development group at Eli Lilly. Previously he was Head of Life Sciences at IP Group and Head of Alliance Management at Antisoma. He brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development. After ten years in R&D positions at Novartis, Sanofi and MDS, Andrew joined the UK biotech sector in 1996 at Antisoma as Head of Clinical Development. He establish the clinical development department which ran several oncology phase I to phase III programmes and later managed their strategic alliance with F Hoffman-La Roche. The role also included in-licensing new drug leads. At IP Group, he managed several portfolio companies and worked with the University partners to create new businesses. Andrew holds a BSc in biochemistry from Queen’s University (Canada), an LLB from the University of London and an MBA from the London Business School.

Research Interest

 Andrew Mackie joined Ergomed as Chief Business Officer in 2015 having worked with the company as a consultant since 2004. He has been instrumental in developing the co-development business and negotiating the partnerships signed to date. Andrew joins from the Business Development group at Eli Lilly. Previously he was Head of Life Sciences at IP Group and Head of Alliance Management at Antisoma. He brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development. After ten years in R&D positions at Novartis, Sanofi and MDS, Andrew joined the UK biotech sector in 1996 at Antisoma as Head of Clinical Development. He establish the clinical development department which ran several oncology phase I to phase III programmes and later managed their strategic alliance with F Hoffman-La Roche. The role also included in-licensing new drug leads. At IP Group, he managed several portfolio companies and worked with the University partners to create new businesses. Andrew holds a BSc in biochemistry from Queen’s University (Canada), an LLB from the University of London and an MBA from the London Business School.

Global Experts from Aruba

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America